9,716 Shares in Sanofi (NASDAQ:SNY) Acquired by Sagespring Wealth Partners LLC

Sagespring Wealth Partners LLC bought a new position in shares of Sanofi (NASDAQ:SNY - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 9,716 shares of the company's stock, valued at approximately $469,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Synergy Asset Management LLC bought a new stake in shares of Sanofi in the fourth quarter valued at $25,000. McClarren Financial Advisors Inc. grew its stake in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after buying an additional 543 shares in the last quarter. Bessemer Group Inc. raised its holdings in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares during the period. Lee Danner & Bass Inc. bought a new stake in Sanofi during the 4th quarter valued at $31,000. Finally, Sierra Ocean LLC bought a new position in Sanofi in the 4th quarter worth about $44,000. Institutional investors own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. BNP Paribas assumed coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $63.33.

Sanofi Trading Up 0.2 %

Shares of SNY stock traded up $0.08 during mid-day trading on Monday, reaching $50.98. The stock had a trading volume of 272,203 shares, compared to its average volume of 2,342,602. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock's 50-day moving average price is $54.73 and its two-hundred day moving average price is $52.14. The firm has a market capitalization of $128.79 billion, a PE ratio of 20.47, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a dividend of $2.0369 per share. The ex-dividend date is Friday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi's payout ratio is currently 64.26%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.